Kimberly Kanada, MD
Dermatology · Sunnyvale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kanada’s office at (408) 739-6000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A127204 · Current
Licensed to practise in California · since 2013 · expires 2027-08-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$161,997
Medicare paid this office $161,997 for 456 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 203 | $34,590 | $109 |
| Short return visit (20+ min) | 278 | $30,657 | $74 |
| Biopsy of related skin growth, first growth | 148 | $17,405 | $90 |
| Destruction of skin growth, 1-14 growths | 103 | $14,621 | $106 |
| Destruction of precancer skin growth, 15 or more growths | 51 | $12,426 | $168 |
See all 16 services
| Return visit (30+ min) | 203 | $34,590 | $109 |
| Short return visit (20+ min) | 278 | $30,657 | $74 |
| Biopsy of related skin growth, first growth | 148 | $17,405 | $90 |
| Destruction of skin growth, 1-14 growths | 103 | $14,621 | $106 |
| Destruction of precancer skin growth, 15 or more growths | 51 | $12,426 | $168 |
| Destruction of precancer skin growth, 1 growth | 179 | $11,855 | $48 |
| Destruction of precancer skin growth, 2-14 growths | 144 | $7,256 | $7 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 15 | $5,306 | $312 |
| Application of ultraviolet light to skin | 21 | $4,371 | $25 |
| Punch biopsy, first skin growth | 28 | $3,784 | $126 |
| Biopsy of related skin growth, each additional growth | 46 | $3,703 | $51 |
| New patient visit (30+ min) | 36 | $2,808 | $78 |
| New patient visit (45+ min) | 20 | $2,058 | $103 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 13 | $1,878 | $134 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 15 | $1,726 | $115 |
| Short return visit | 13 | $673 | $52 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 734 | More than 90% of doctors who do this |
| Removal or shaving of skin growth | 30 | More than 75% of doctors who do this |
| Skin biopsy | 420 | More than 94% of doctors who do this |
Who their Medicare patients are
456 Original Medicare patients in 2024. Average age 75 · Under 65 3% · 85 and older 12% · Women 55% · Also on Medicaid 7% · Health risk score 0.84. At or below the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 57% · Chronic kidney disease 17% · Diabetes 16% · Coronary heart disease 15% · Cancer 14% · Atrial fibrillation 10% · Depression 10% · Heart failure 7% · COPD 5% · Dementia 4% · Stroke 3%.
The office billed $598,424, Medicare allowed $227,472 and paid $161,997; for 2,921 services of 41 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 456 | 2,921 | 75 | 0.84 | $598,424 | $161,997 |
| 2023 | 454 | 2,503 | 75 | 0.87 | $451,843 | $132,345 |
| 2022 | 218 | 1,028 | 74 | 0.78 | $179,270 | $51,281 |
| 2021 | 235 | 1,335 | 75 | 0.93 | $260,535 | $77,947 |
| 2020 | 175 | 727 | 75 | 1.17 | $148,221 | $43,044 |
| 2019 | 258 | 1,203 | 76 | 0.98 | $258,325 | $67,870 |
| 2018 | 242 | 970 | 74 | 0.99 | $180,165 | $50,256 |
| 2017 | 314 | 1,112 | 74 | 0.98 | $223,867 | $61,490 |
| 2016 | 83 | 181 | 73 | 0.98 | $42,149 | $12,114 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Short return visit (20+ min) | 241 | $27,197 | $76 |
| Return visit (30+ min) | 159 | $24,279 | $112 |
| Biopsy of related skin growth, first growth | 107 | $10,620 | $92 |
| Destruction of skin growth, 1-14 growths | 79 | $10,290 | $105 |
| Destruction of precancer skin growth, 1 growth | 145 | $9,972 | $50 |
| Destruction of precancer skin growth, 15 or more growths | 33 | $8,112 | $173 |
| New patient visit (30+ min) | 65 | $5,848 | $90 |
| Destruction of precancer skin growth, 2-14 growths | 117 | $5,698 | $7 |
| New patient visit (45+ min) | 37 | $5,532 | $150 |
| Punch biopsy, first skin growth | 33 | $4,402 | $133 |
| Application of ultraviolet light to skin | 21 | $2,700 | $24 |
| Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | 15 | $1,862 | $116 |
| Biopsy of related skin growth, each additional growth | 27 | $1,476 | $48 |
| New patient visit (15+ min) | 12 | $724 | $60 |
2022: 12 services
| Return visit (30+ min) | 76 | $8,805 | $99 |
| Short return visit (20+ min) | 102 | $8,342 | $69 |
| Biopsy of related skin growth, first growth | 48 | $4,761 | $92 |
| Destruction of skin growth, 1-14 growths | 32 | $4,207 | $108 |
| Destruction of precancer skin growth, 15 or more growths | 18 | $3,330 | $159 |
| Destruction of precancer skin growth, 1 growth | 61 | $3,249 | $46 |
| Application of ultraviolet light to skin | 18 | $2,787 | $26 |
| Destruction of precancer skin growth, 2-14 growths | 50 | $2,756 | $7 |
| New patient visit (30+ min) | 24 | $2,204 | $92 |
| Punch biopsy, first skin growth | 16 | $2,017 | $126 |
| Biopsy of related skin growth, each additional growth | 20 | $1,736 | $54 |
| New patient visit (45+ min) | 12 | $1,375 | $115 |
2021: 11 services
| Return visit (30+ min) | 97 | $15,830 | $110 |
| Short return visit (20+ min) | 133 | $14,400 | $74 |
| Biopsy of related skin growth, first growth | 58 | $6,899 | $100 |
| Destruction of skin growth, 1-14 growths | 38 | $5,283 | $108 |
| Destruction of precancer skin growth, 1 growth | 75 | $4,786 | $45 |
| Punch biopsy, first skin growth | 22 | $3,267 | $136 |
| Destruction of precancer skin growth, 2-14 growths | 62 | $3,118 | $7 |
| Application of ultraviolet light to skin | 11 | $2,443 | $26 |
| New patient visit (30+ min) | 24 | $2,260 | $94 |
| Biopsy of related skin growth, each additional growth | 21 | $2,089 | $55 |
| New patient visit (15+ min) | 11 | $568 | $52 |
2020: 9 services
| Return visit (30+ min) | 72 | $7,817 | $97 |
| Short return visit (20+ min) | 63 | $4,824 | $65 |
| Destruction of skin growth, 1-14 growths | 31 | $3,966 | $117 |
| Biopsy of related skin growth, first growth | 27 | $2,841 | $92 |
| Destruction of precancer skin growth, 1 growth | 45 | $2,369 | $43 |
| Punch biopsy, first skin growth | 13 | $1,810 | $129 |
| Destruction of precancer skin growth, 2-14 growths | 39 | $1,671 | $6 |
| New patient visit (30+ min) | 19 | $1,650 | $87 |
| New patient visit (15+ min) | 20 | $1,482 | $74 |
2019: 12 services
| Return visit (30+ min) | 145 | $17,344 | $92 |
| Biopsy of related skin growth, first growth | 64 | $6,613 | $92 |
| Destruction of precancer skin growth, 1 growth | 92 | $5,432 | $46 |
| Short return visit (20+ min) | 80 | $4,949 | $53 |
| New patient visit (30+ min) | 41 | $3,375 | $82 |
| Destruction of skin growth, 1-14 growths | 30 | $3,320 | $98 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 11 | $3,069 | $279 |
| Punch biopsy, first skin growth | 23 | $3,020 | $126 |
| Destruction of precancer skin growth, 2-14 growths | 78 | $2,475 | $6 |
| Biopsy of related skin growth, each additional growth | 13 | $1,199 | $54 |
| New patient visit (15+ min) | 15 | $1,040 | $69 |
| Short return visit | 20 | $814 | $35 |
2018: 11 services
| Return visit (30+ min) | 99 | $12,140 | $87 |
| Destruction of skin growth, 1-14 growths | 48 | $6,102 | $107 |
| Biopsy of single growth of skin and/or tissue | 50 | $5,311 | $93 |
| Short return visit (20+ min) | 67 | $4,824 | $57 |
| New patient visit (30+ min) | 56 | $4,665 | $83 |
| Destruction of precancer skin growth, 1 growth | 62 | $4,073 | $50 |
| Application of ultraviolet light to skin | 20 | $2,885 | $21 |
| Short return visit | 39 | $1,852 | $37 |
| Destruction of precancer skin growth, 2-14 growths | 44 | $1,138 | $5 |
| New patient visit (15+ min) | 19 | $1,034 | $54 |
| Biopsy of each additional growth of skin and/or tissue | 11 | $369 | $31 |
2017: 10 services
| Return visit (30+ min) | 105 | $11,419 | $89 |
| New patient visit (30+ min) | 124 | $10,004 | $81 |
| Biopsy of single growth of skin and/or tissue | 69 | $7,685 | $96 |
| Short return visit (20+ min) | 82 | $5,362 | $59 |
| Destruction of skin growth, 1-14 growths | 36 | $4,504 | $107 |
| Destruction of precancer skin growth, 1 growth | 63 | $3,787 | $49 |
| Application of ultraviolet light to skin | 16 | $2,816 | $22 |
| Short return visit | 39 | $1,516 | $34 |
| Destruction of precancer skin growth, 2-14 growths | 54 | $1,474 | $5 |
| New patient visit (15+ min) | 24 | $1,138 | $47 |
2016: 6 services
| Return visit (30+ min) | 30 | $3,121 | $101 |
| New patient visit (30+ min) | 21 | $1,867 | $89 |
| Biopsy of single growth of skin and/or tissue | 15 | $1,474 | $98 |
| Destruction of precancer skin growth, 1 growth | 14 | $873 | $58 |
| Short return visit (20+ min) | 12 | $824 | $69 |
| Destruction of precancer skin growth, 2-14 growths | 11 | $187 | $5 |
Drugs they prescribed that Part D paid
$387,514
Pharmacies billed $387,514 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 618) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
550 generic and 68 brand-name prescriptions · $387,514 in drug cost · 19 antibiotic prescriptions to 13 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Taltz | 22 | $152,089 | $6,913 |
| Otezla | 15 | $113,904 | $7,594 |
| Calcipotriene | 20 | $2,650 | $133 |
| Tacrolimus | 20 | $1,933 | $97 |
| Fluorouracil | 31 | $1,786 | $58 |
See all 15 drugs
| Taltz | 22 | $152,089 | $6,913 |
| Otezla | 15 | $113,904 | $7,594 |
| Calcipotriene | 20 | $2,650 | $133 |
| Tacrolimus | 20 | $1,933 | $97 |
| Fluorouracil | 31 | $1,786 | $58 |
| Fluocinonide | 45 | $1,172 | $26 |
| Clobetasol Propionate | 41 | $805 | $20 |
| Ketoconazole | 54 | $752 | $14 |
| Triamcinolone Acetonide | 49 | $730 | $15 |
| Mometasone Furoate | 17 | $271 | $16 |
| Hydrocortisone | 48 | $236 | $5 |
| Mupirocin | 27 | $180 | $7 |
| Nystatin | 18 | $173 | $10 |
| Terbinafine | 15 | $136 | $9 |
| Clindamycin Phosphate | 14 | $136 | $10 |
Year by year
| 2024 | 618 | 205 | 0% (0) | 11% | $387,514 |
| 2023 | 467 | 205 | 0% (0) | None | $86,469 |
| 2022 | 250 | 107 | 0% (0) | 11% | $136,730 |
| 2021 | 420 | 140 | 0% (0) | 11% | $198,458 |
| 2020 | 200 | 90 | 0% (0) | 20% | $127,460 |
| 2019 | 294 | 117 | 0% (0) | 16% | $122,151 |
| 2018 | 276 | 95 | 0% (0) | 13% | $68,551 |
| 2017 | 311 | 118 | 0% (0) | 10% | $19,588 |
| 2016 | 49 | 28 | 0% (0) | None | $2,845 |
| 2015 | 64 | 23 | 0% (0) | None | $8,054 |
| 2014 | 55 | 22 | 0% (0) | None | $4,554 |
| 2013 | 22 | 11 | 0% (0) | None | $48,271 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 14 drugs
| Tacrolimus | 20 | $4,230 | $211 |
| Fluorouracil | 34 | $3,565 | $105 |
| Fluocinonide | 35 | $1,980 | $57 |
| Clobetasol Propionate | 27 | $944 | $35 |
| Ketoconazole | 36 | $938 | $26 |
| Clindamycin Phosphate | 15 | $921 | $61 |
| Triamcinolone Acetonide | 46 | $572 | $12 |
| Hydrocortisone | 37 | $274 | $7 |
| Mupirocin | 27 | $244 | $9 |
| Doxycycline Hyclate | 13 | $242 | $19 |
| Mometasone Furoate | 18 | $220 | $12 |
| Gabapentin | 17 | $193 | $11 |
| Clotrimazole | 14 | $190 | $14 |
| Methotrexate | 11 | $185 | $17 |
2022: 6 drugs
| Otezla | 13 | $53,782 | $4,137 |
| Clobetasol Propionate | 25 | $2,408 | $96 |
| Fluocinonide | 12 | $952 | $79 |
| Triamcinolone Acetonide | 34 | $237 | $7 |
| Mupirocin | 16 | $176 | $11 |
| Hydrocortisone | 15 | $129 | $9 |
2021: 12 drugs
| Clobetasol Propionate | 35 | $2,434 | $70 |
| Betamethasone Dipropionate | 28 | $2,100 | $75 |
| Fluocinonide | 28 | $1,664 | $59 |
| Fluorouracil | 11 | $1,243 | $113 |
| Ketoconazole | 34 | $925 | $27 |
| Betamethasone Diprop Augmented | 16 | $755 | $47 |
| Triamcinolone Acetonide | 47 | $671 | $14 |
| Nystop | 11 | $406 | $37 |
| Mupirocin | 30 | $270 | $9 |
| Terbinafine | 19 | $164 | $9 |
| Hydrocortisone | 24 | $153 | $6 |
| Folic Acid | 12 | $55 | $5 |
2020: 7 drugs
| Humira | 11 | $59,348 | $5,395 |
| Betamethasone Dipropionate | 21 | $1,699 | $81 |
| Fluocinonide | 20 | $1,043 | $52 |
| Ketoconazole | 20 | $401 | $20 |
| Triamcinolone Acetonide | 25 | $215 | $9 |
| Clotrimazole | 13 | $195 | $15 |
| Hydrocortisone | 12 | $88 | $7 |
2019: 8 drugs
| Ketoconazole | 37 | $1,201 | $32 |
| Clobetasol Propionate | 13 | $988 | $76 |
| Triamcinolone Acetonide | 48 | $951 | $20 |
| Betamethasone Dipropionate | 11 | $864 | $79 |
| Fluocinonide | 14 | $739 | $53 |
| Betamethasone Diprop Augmented | 12 | $295 | $25 |
| Hydrocortisone | 37 | $201 | $5 |
| Nystatin | 11 | $140 | $13 |
2018: 10 drugs
| Fluocinonide | 29 | $1,885 | $65 |
| Methotrexate | 13 | $1,744 | $134 |
| Clobetasol Propionate | 14 | $1,113 | $79 |
| Betamethasone Dipropionate | 13 | $792 | $61 |
| Ketoconazole | 18 | $722 | $40 |
| Triamcinolone Acetonide | 47 | $667 | $14 |
| Betamethasone Diprop Augmented | 13 | $577 | $44 |
| Prednisone | 12 | $164 | $14 |
| Hydrocortisone | 19 | $151 | $8 |
| Nystatin | 13 | $123 | $9 |
2017: 9 drugs
| Clobetasol Propionate | 16 | $2,265 | $142 |
| Fluocinonide | 27 | $1,976 | $73 |
| Ketoconazole | 30 | $1,373 | $46 |
| Betamethasone Dipropionate | 11 | $870 | $79 |
| Methotrexate | 11 | $836 | $76 |
| Betamethasone Dipropionate | 11 | $745 | $68 |
| Triamcinolone Acetonide | 69 | $606 | $9 |
| Doxycycline Monohydrate | 11 | $294 | $27 |
| Hydrocortisone | 23 | $211 | $9 |
Money from drug and device companies
$430 in 2025
| 2025 | 7 | 14 | None | $430 |
| 2024 | 9 | 15 | None | $446 |
| 2019 | 1 | 1 | None | $124 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genzyme | Dupixent | $167 | 2 payments
|
| Lilly USA | Taltz | $96 | 4 payments
|
| Galderma Laboratories L.P. | Nemluvio | $62 | 3 payments
|
| Arcutis Biotherapeutics | Zoryve | $34 | 2 payments
|
| Incyte | Opzelura | $31 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $22 | 1 payment
|
See all 14 published payments
| Galderma Laboratories L.P. | Meals · 2025-10-27 | Nemluvio | $26 |
| Lilly USA | Meals · 2025-10-13 | Taltz | $32 |
| Galderma Laboratories L.P. | Meals · 2025-08-11 | None | $18 |
| Lilly USA | Meals · 2025-07-26 | Taltz | $17 |
| Abbvie | Meals · 2025-07-01 | Skyrizi | $17 |
| Galderma Laboratories L.P. | Meals · 2025-05-19 | Nemluvio | $19 |
| Genzyme | Meals · 2025-05-01 | Dupixent | $125 |
| Lilly USA | Meals · 2025-04-28 | Taltz | $25 |
| Incyte | Meals · 2025-04-22 | Opzelura | $31 |
| Arcutis Biotherapeutics | Meals · 2025-04-14 | Zoryve | $18 |
| Lilly USA | Meals · 2025-03-24 | Ebglyss | $22 |
| Genzyme | Meals · 2025-02-03 | Dupixent | $42 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-13 | Sotyktu | $22 |
| Arcutis Biotherapeutics | Meals · 2025-01-10 | Zoryve | $16 |
See earlier years (2024, 2019)
2024: $446
| E.R. Squibb & Sons L.L.C. | Sotyktu | $131 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $83 | 3 payments
|
| Genzyme | Dupixent | $83 | 2 payments
|
| Abbvie | Skyrizi | $35 | 1 payment
|
| Incyte | Opzelura | $26 | 1 payment
|
| Pfizer | Litfulo | $25 | 1 payment
|
| Lilly USA | Taltz | $25 | 1 payment
|
| Almirall | Klisyri | $20 | 1 payment
|
| Arcutis Biotherapeutics | Zoryve | $18 | 1 payment
|
2019: $124
| Ucb | None | $124 | 1 payment
|
Professional record
- NPI
- 1912265752
- Licence
- CA A127204California A127204: Current · expires 2027-08-31
- Trained
- University of California, San Diego School of Medicine, 2012
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X); Student in a training program (390200000X)
- Mailing address
- 2350 W. El Camino Real, 2nd Floor, Mountain View, CA, 94040
- NPI first listed
- 2012-04-30
- NPI last updated
- 2016-10-07
This is when the NPI record was last certified, not a medical board exam.